Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—including popular medications such as Ozempic, Wegovy, Mounjaro, and Zepbound—are prescribed for managing type 2 diabetes and obesity by regulating blood sugar and appetite. These medications can delay gastric emptying, potentially affecting how oral drugs are absorbed in the digestive system. One critical concern is whether GLP-1 RAs interfere with oral hormonal contraceptives’ effectiveness. According to clinical pharmacology data and expert recommendations, certain GLP-1 RAs like Zepbound slow down gastric emptying, which can impair the absorption of medications taken concurrently by mouth. This includes oral contraceptive pills that rely on consistent absorption to maintain effective hormone levels. Studies suggest that GLP-1 RAs may temporarily reduce the efficacy of oral birth control methods due to this absorption delay. As a result, healthcare providers often recommend that women using oral contraceptives who start GLP-1 RA treatments should consider additional or alternative non-oral contraceptive methods, such as intrauterine devices (IUDs), contraceptive implants, or barrier methods, during the treatment period and for at least four weeks following dose escalation. It is especially important to monitor and manage this interaction because unintended pregnancy has serious implications. The phrase “Your birth control doesn’t work on GLP1s and then BOOM pregnant!” highlights patient concerns stemming from the drug interaction risk due to reduced hormonal contraceptive effectiveness. Not all GLP-1 RAs impact birth control equivalently; for example, tirzepatide might have less or no known effect on hormonal contraceptives, but comprehensive individual evaluation is essential. Patients prescribed GLP-1 medications should always consult with their healthcare providers about their contraceptive options and any necessary adjustments. Awareness and cautious use of concomitant medications can prevent unplanned pregnancies and maintain therapeutic effectiveness. This guidance aligns with FDA recommendations and clinical best practices emphasizing patient safety and informed decision-making. In summary, while GLP-1 receptor agonists are effective for metabolic conditions, their influence on the absorption of oral birth control pills requires caution. Supplementing oral contraceptives with non-oral methods or barrier protection during GLP-1 treatment initiation and dose changes is prudent to ensure reliable contraception.